Drugs / Empegfilgrastim
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01569087 | May 2012 → Jan 2013 | neutropenia | Biocad | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02104830 | Sep 2013 → Jun 2014 | neutropenia | Biocad | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | empegfilgrastim | “BCD-017-2 is an open-label randomized phase II clinical study to compare the incidence of CTCAE grade 3/4 neutropenia after a single administration of recombinant human...” NCT01569087 ↗1“Empegfilgrastim is supplied as solution for injection 3 mg/ml.” NCT02104830 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human pegylated filgrastim empegfilgrastim” NCT01569087 ↗ |
| Route | Subcutaneous | “single administration of empegfilgrastim at a dose of 3 mg subcutaneously” NCT01569087 ↗ |